OA
TEVA icon

Oak Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Oak Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-782,189
Closed -$12.3M – 153
2019
Q1 		$12.3M Buy
782,189
+21,181
+3% +$374K 0.75% 41
2018
Q4 		$11.7M Buy
761,008
+75,980
+11% +$1.56M 0.83% 41
2018
Q3 		$14.8M Buy
685,028
+127,215
+23% +$2.95M 0.9% 39
2018
Q2 		$13.6M Buy
557,813
+5,030
+0.9% +$103K 0.91% 37
2018
Q1 		$9.45M Buy
552,783
+169,808
+44% +$3.32M 0.66% 51
2017
Q4 		$7.26M Sell
382,975
-1,249
-0.3% -$18.8K 0.51% 57
2017
Q3 		$6.76M Buy
384,224
+4,300
+1% +$96.8K 0.5% 59
2017
Q2 		$12.6M Buy
379,924
+2,114
+0.6% +$65.4K 0.95% 36
2017
Q1 		$12.1M Buy
377,810
+7,896
+2% +$269K 0.97% 33
2016
Q4 		$13.4M Sell
369,914
-24,824
-6% -$991K 1.32% 23
2016
Q3 		$16.9M Buy
394,738
+38,015
+11% +$1.98M 1.74% 17
2016
Q2 		$17.9M Buy
356,723
+881
+0.2% +$46.9K 2.15% 14
2016
Q1 		$19M Sell
355,842
-2,109
-0.6% -$124K 2.33% 14
2015
Q4 		$23.5M Sell
357,951
-20,148
-5% -$1.25M 2.8% 11
2015
Q3 		$21.3M Sell
378,099
-5,864
-2% -$380K 2.83% 9
2015
Q2 		$22.7M Sell
383,963
-2,450
-0.6% -$151K 2.76% 9
2015
Q1 		$24.1M Buy
386,413
+9,841
+3% +$572K 2.9% 8
2014
Q4 		$21.7M Buy
376,572
+1,226
+0.3% +$68.3K 2.59% 10
2014
Q3 		$20.2M Buy
375,346
+14,940
+4% +$792K 2.49% 12
2014
Q2 		$18.9M Buy
360,406
+12,056
+3% +$616K 2.31% 13
2014
Q1 		$18.4M Sell
348,350
-93,899
-21% -$4.34M 2.28% 14
2013
Q4 		$17.7M Buy
+442,249
New +$17.4M 1.92% 18
2013
Q2 		$18.1M Buy
+462,508
New +$18M 2.16% 18

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Oak Associates's TEVA Position: Q2 2019 in Review

Oak Associates sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 782,189 shares — an estimated $12.3M sold.

Oak Associates first reported a position in TEVA in Q2 2013 and held it in 23 quarters. The position peaked at $24.1M in Q1 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Oak Associates reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Oak Associates sold 782,189 Teva Pharmaceuticals shares in Q2 2019, an estimated $12.3M.
  • Oak Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Oak Associates's Teva Pharmaceuticals position peaked at $24.1M in Q1 2015.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Oak Associates's 13F filing for Q2 2019, filed 9 Aug 2019.